Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172321 | 0.74 | KDM1A (0.43) | KDM1ASLC6A4TSHRMAPK1BACE1 | |
| SCHEMBL1391271 | 0.73 | DHFR (0.43) | KDM1ASLC6A4TSHRMAPK1BACE1 | |
| SCHEMBL3107125 | 0.70 | KDM1A (0.42) | KDM1ASLC6A4TSHRMAPK1BACE1 | |
| SCHEMBL6232785 | 0.69 | KDM1A (0.43) | KDM1ASLC6A4TSHRMAPK1BACE1 | |
| SCHEMBL3614612 | 0.68 | TAAR1 (0.51) | — | |
| SCHEMBL3614002 | 0.68 | TAAR1 (0.51) | — | |
| SCHEMBL3613998 | 0.68 | TAAR1 (0.51) | — | |
| SCHEMBL3107121 | 0.68 | KDM1A (0.42) | KDM1ASLC6A4TSHRMAPK1BACE1 | |
| SCHEMBL1420518 | 0.66 | KDM1A (0.59) | KDM1ASLC6A4TSHRMAPK1SLC6A3 | |
| SCHEMBL23648828 | 0.66 | KDM1A (0.54) | KDM1ASLC6A4TSHRMAPK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2964620-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| CN-104995179-A | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN LA ROCHE | 2015-10-21 | — | — | CN | disclosed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HAVCR2, UGT1A1, UGT1A3 | KDM1A 2656/4885SLC6A4 1583/4885TSHR 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.